To recover your password please fill in your email address
Please fill in below form to create an account with us
A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT)
See ANZCTR for full trial details >
|
Trial Summary: |
This study aims to develop a new treatment for glioblastoma (GBM), by finding out whether giving veliparib (an oral PARPi inhibitor drug) in combination with radiotherapy and follow up chemotherapy will improve the outcome of patients with unmethylated MGMT glioblastoma (GBM). The study will also find out how long the GBM responds to this treatment, the side effects of the treatment and the effect on quality of life. |
|
Supported By: |
Cure Brain Cancer Foundation; AbbVie; Cancer Council New South Wales (CCNSW) COGNO; NHMRC CTC |
|
Eligibility: |
Newly diagnosed patients with histologically confirmed GBM (WHO grade IV) following surgery, with unmethylated MGMT promoter gene. |
|
Registration ID: |
ACTRN12615000407594 |
|
Participation: |
Australia |
|
Australian Lead Group: |
COGNO |
|
Status: |
In follow up |
|
Activation Date: |
28/10/2015 |
|
Chairs: |
A/Prof Mustafa Khasraw |
|
Contact: |